Anhui Anke Biotechnology (Group) Co., Ltd.
Profile managed by Bizz IdDescription
Products
12 productsANKEBIO anti-PD1 Product.
Finished product (FDF)
Verified on 2026-10-21
Bevacizumab biosimilar, anti-VEGF (ANKEBIO anti-VEGF Product).
Finished product (FDF)
Verified on 2026-10-21
Brand: Anterferon. Recombinant human interferon alpha 2b (rDNA origin). Cream. Verruca acuminata (HPV), herpes labialis and genital herpes.
Finished product (FDF)
Verified on 2026-10-21
Brand: Anterferon. Recombinant human interferon alpha 2b (rDNA origin). Eye drops. Herpes simplex keratitis.
Finished product (FDF)
Verified on 2026-10-21
Brand: Anterferon. Recombinant human interferon alpha 2b (rDNA origin). Liquid for injection. Acute and chronic hepatitis (B or C), condylomata acuminata, hairy cell leukemia, chronic granulocytic leukemia.
Finished product (FDF)
Verified on 2026-10-21
Brand: Anterferon. Recombinant human interferon alpha 2b (rDNA origin). Lyophilized powder for injection. Acute and chronic hepatitis (B or C), condylomata acuminata, hairy cell leukemia, chronic granulocytic leukemia.
Finished product (FDF)
Verified on 2026-10-21
Brand: Anterferon. Recombinant human interferon alpha 2b (rDNA origin). Prefilled syringe for injection. Acute and chronic hepatitis (B or C), condylomata acuminata, hairy cell leukemia, chronic granulocytic leukemia.
Finished product (FDF)
Verified on 2026-10-21
Brand: Anterferon. Recombinant human interferon alpha 2b (rDNA origin). Suppository. Cervical erosion by viral infection.
Finished product (FDF)
Verified on 2026-10-21
Recombinant human type III collagen (rhColIII).
Other
Verified on 2026-10-21
Brand: Ansomone. Recombinant human growth hormone (191 aa, E. coli), lyophilized for injection; EP/USP/CP/WHO standard. Growth hormone deficiency, Turner syndrome, kidney failure.
Finished product (FDF)
Verified on 2026-10-21
Brand: Ansomone. Recombinant human growth hormone pre-filled syringe; EP/USP/CP/WHO standard. Growth failure in children due to growth hormone deficiency.
Finished product (FDF)
Verified on 2026-10-21
Brand: Ansaiting (安赛汀), trastuzumab for injection 150 mg/vial. HER2+ metastatic and early breast cancer; HER2+ metastatic gastric or GEJ adenocarcinoma.
Finished product (FDF)
Verified on 2026-10-21